Clinical Scorecard: Comparative Analysis of Direct In-Bore MRI-Guided Biopsy Versus Fusion-Guided Biopsy in Patients with MRI Detected Lesions Suggestive of Clinically Significant Prostate Cancer

At a Glance

Key Highlights

• mpMRI is recommended by EAU for men with persistent suspicion of PCa after negative TRUS biopsy due to improved detection of csPCa
• MRGB offers accurate lesion targeting but is time-consuming, expensive, and less accessible; FGB is more widely available and less costly
• FGB allows concurrent systematic TRUS biopsy to detect csPCa missed by targeted biopsy alone, but in this study only targeted biopsy was performed

Guideline-Based Recommendations

Diagnosis

• Use mpMRI to detect and localize suspicious prostate lesions prior to biopsy
• Consider targeted biopsy for lesions scored PI-RADS 4 or 5 and ≥8 mm in size
• Perform biopsy in patients with prior negative TRUS biopsy but persistent clinical suspicion

Management

• Select biopsy method based on lesion size, availability, and patient preference: MRGB for smaller or PI-RADS 3 lesions, FGB for larger lesions ≥8 mm
• Perform targeted biopsy without anesthetics in both MRGB and FGB procedures
• In FGB, use software-assisted image fusion with electromagnetic tracking and cognitive enhancement

Monitoring & Follow-up

• Evaluate biopsy cores by dedicated uropathologists considering Gleason score ≥7 as clinically significant
• Use PI-RADS scoring and lesion size to guide biopsy targeting and follow-up

Risks

• MRGB is time-consuming (45–60 min) and expensive with limited accessibility
• FGB may have registration inaccuracies due to prostate deformation and lacks needle position confirmation
• Both procedures performed transrectally without anesthetics may cause patient discomfort

Patient & Prescribing Data

Patients with prior negative TRUS biopsy, PI-RADS 4 or 5 lesions ≥8 mm on mpMRI

FGB performed by less experienced radiologists can be as accurate as MRGB for lesions ≥8 mm; patient preference influences biopsy method selection

Clinical Best Practices

• Use mpMRI with PI-RADS scoring to select patients and lesions for targeted biopsy
• Apply software-assisted fusion with electromagnetic tracking and cognitive enhancement for FGB
• Confirm lesion localization with additional MRI sequences during MRGB and verify needle placement
• Consider lesion size and PI-RADS score when choosing between MRGB and FGB
• Perform biopsies without anesthetics but monitor patient comfort
• Evaluate biopsy specimens with experienced uropathologists aware of biopsy method and imaging findings

References

• European Association of Urology Guidelines on Prostate Cancer
• PI-RADS Prostate Imaging Reporting and Data System